Axsome Therapeutics, Inc. (AXSM)
Automate Your Wheel Strategy on AXSM
With Tiblio's Option Bot, you can configure your own wheel strategy including AXSM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AXSM
- Rev/Share 8.8428
- Book/Share 1.0887
- PB 96.1165
- Debt/Equity 3.936
- CurrentRatio 2.0279
- ROIC -0.7654
- MktCap 5152096896.0
- FreeCF/Share -2.4196
- PFCF -43.5695
- PE -18.3773
- Debt/Assets 0.351
- DivYield 0
- ROE -3.6379
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | AXSM | Jefferies | -- | Buy | -- | $200 | April 7, 2025 |
| Initiation | AXSM | Deutsche Bank | -- | Buy | -- | $176 | Feb. 11, 2025 |
| Reiterated | AXSM | Mizuho | -- | Outperform | $124 | $122 | Dec. 31, 2024 |
| Initiation | AXSM | Wells Fargo | -- | Overweight | -- | $140 | Sept. 3, 2024 |
News
Axsome Therapeutics Q1: Marketing-Driven Growth Masks Profitability Concerns
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Positive
Axsome Therapeutics reported strong Q1 2025 earnings, with revenue and EPS beats driven by Auvelity and Sunosi, despite high SG&A expenses and net loss. Auvelity shows promising growth in the competitive depression market, but its success is heavily reliant on aggressive marketing and significant spending. Upcoming launches and regulatory submissions for Symbravo, AXS-14, AXS-05, and AXS-12 face stiff competition and potential regulatory hurdles.
Read More
AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Axsome reports better-than-expected first quarter 2025 results. Net product revenues surge year over year on strong Auvelity sales.
Read More
Axsome Therapeutics, Inc. (AXSM) Q1 2025 Earnings Call Transcript
Published: May 05, 2025 by: Seeking Alpha
Sentiment: Neutral
Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q1 2025 Earnings Conference Call May 5, 2025 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - CEO Nick Pizzie - CFO Ari Maizel - Chief Commercial Officer Mark Jacobson - COO Hunter Murdock - General Counsel Conference Call Participants Leonid Timashev - RBC Capital Markets Marc Goodman - Leerink Partners Andrew Tsai - Jefferies Ash Verma - UBS Ram Selvaraju - H.C. Wainwright Charles Duncan - Cantor Fitzgerald David Amsellem - Piper Sandler David Hoang - Deutsche Bank Joon Lee - Truist Securities Cerena Chen - Wells Fargo Jason …
Read More
Axsome Therapeutics Clocks Around 60% Topline Growth In Q1
Published: May 05, 2025 by: Benzinga
Sentiment: Positive
Axsome Therapeutics Inc AXSM on Monday reported first-quarter 2025 revenues of $121.5 million, up from $75 million a year ago, beating the consensus of $119.87 million.
Read More
Axsome (AXSM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Axsome Therapeutics (AXSM) Reports Q1 Loss, Tops Revenue Estimates
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Negative
Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to loss of $1.09 per share a year ago.
Read More
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Published: April 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 22, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in four upcoming investor conferences in May:
Read More
Kuehn Law Encourages Investors of Five Below, Inc. to Contact Law Firm
Published: April 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Five Below, Inc. (NASDAQ: FIVE) breached their fiduciary duties to shareholders.
Read More
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm
Published: April 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties to shareholders.
Read More
Axsome (AXSM) Moves 4.2% Higher: Will This Strength Last?
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Axsome (AXSM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Read More
Kuehn Law Encourages Investors of Axsome Therapeutics, Inc. to Contact Law Firm
Published: April 08, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , April 8, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Axsome Therapeutics, Inc. (NASDAQ: AXSM) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Axsome caused the company to misrepresent or fail to disclose (i) Axsome's chemistry, manufacturing, and control ("CMC") practices were deficient with respect to AXS-07 and its manufacturing process; (ii) as a result, Axsome was unlikely to submit the AXS-07 NDA on its initially represented timeline; (iii) the foregoing CMC issues remained unresolved at the time that the …
Read More
Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer's Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting
Published: April 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
Late-breaking oral presentation of results from the positive pivotal ACCORD-2 Phase 3 trial of AXS-05 in Alzheimer's disease agitation
Read More
AXSM Stock Down on Top-Line Data From Depression Study on Solriamfetol
Published: April 02, 2025 by: Zacks Investment Research
Sentiment: Negative
Axsome's phase III PARADIGM study evaluating solriamfetol in major depressive disorder fails to show a statistically significant change in the primary endpoint.
Read More
Why Shares of Axsome Therapeutics Slumped Today
Published: April 01, 2025 by: The Motley Fool
Sentiment: Negative
Shares of biopharmaceutical company Axsome Therapeutics (AXSM -6.29%) had declined 6% at 11 a.m. ET today. The slump comes after the company announced the results of a phase 3 trial of solriamfetol (brand name Sunosi) in major depressive disorder (MDD).
Read More
AXSM Stock Down Despite ADHD Study Meeting Primary Endpoint
Published: March 26, 2025 by: Zacks Investment Research
Sentiment: Negative
Axsome's phase III FOCUS study, evaluating solriamfetol for treating attention deficit hyperactivity disorder, meets its primary and key secondary endpoints.
Read More
Axsome: The Alzheimer's Agitation Program For AXS-05
Published: March 21, 2025 by: Seeking Alpha
Sentiment: Positive
Axsome's AXS-05 shows strong efficacy in treating Alzheimer's Disease Agitation, with significant CMAI score reductions in multiple Phase 3 trials. The FDA has greenlit Axsome to submit an sNDA for AXS-05 without requiring new trials, based on robust existing data. AXS-05 demonstrates a favorable safety profile with low discontinuation rates due to adverse events, unlike competitors such as AVP-786 and brexpiprazole.
Read More
Will Auvelity & Other Drugs Aid AXSM's Growth Amid Stiff Competition?
Published: March 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Axsome's depression drug, Auvelity, is driving the top line while Sunosi diversifies its business. The recent FDA nod for Symbravo also bodes well.
Read More
AXSM Settles Sunosi Patent Litigation With Hikma Pharmaceuticals
Published: March 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Axsome enters into a settlement agreement with Hikma Pharmaceuticals to resolve a patent litigation related to Sunosi.
Read More
Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs
Published: February 24, 2025 by: Benzinga
Sentiment: Positive
On Monday, Axsome Therapeutics, Inc. AXSM announced that the EMERGE Phase 3 trial of Symbravo (MoSEIC meloxicam and rizatriptan) in patients experiencing inadequate response to oral CGRP inhibitors (most commonly used drugs for migraine) met its primary endpoint.
Read More
Axsome Q4 Loss Wider Than Expected, Auvelity Drives Sales Growth
Published: February 18, 2025 by: Zacks Investment Research
Sentiment: Positive
AXSM's fourth-quarter 2024 earnings miss estimates while revenues beat the same. Net product sales rise year over year.
Read More
Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade
Published: February 11, 2025 by: Seeking Alpha
Sentiment: Positive
Axsome Therapeutics, Inc.'s stock has surged over 30% since my last “Hold” rating, driven by key catalysts like the litigation settlement with Teva Pharmaceuticals, announced today. Axsome's Auvelity and Sunosi are crucial, with Auvelity expected to generate over 75% of 2025 revenues; as such, today's news is a significant win. Despite high competition in MDD and other markets, Axsome's pipeline, including AXS-07 and AXS-12, shows potential for substantial revenue growth.
Read More
Why Axsome Therapeutics Stock Is Soaring Today
Published: February 11, 2025 by: The Motley Fool
Sentiment: Positive
Shares of Axsome Therapeutics (AXSM 4.36%) are up on Tuesday. The company's stock gained 4.1% as of 10:20 a.m.
Read More
Earnings Preview: Axsome Therapeutics (AXSM) Q4 Earnings Expected to Decline
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Negative
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Axsome Stock Surges 20% on Auvelity Patent Settlement With Teva
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Positive
AXSM stock rises 20% as it settles Auvelity patent litigation with Teva, protecting the drug's exclusivity in the United States at least until Sept. 30, 2038.
Read More
Axsome (AXSM) Surges 20.2%: Is This an Indication of Further Gains?
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Axsome (AXSM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Read More
Why Axsome Therapeutics Stock Is Skyrocketing Today
Published: February 10, 2025 by: The Motley Fool
Sentiment: Positive
Shares of Axsome Therapeutics (AXSM 20.22%) are flying higher on Monday. The company's stock is up 24.7% as of 1:10 p.m.
Read More
About Axsome Therapeutics, Inc. (AXSM)
- IPO Date 2015-11-19
- Website https://www.axsome.com
- Industry Biotechnology
- CEO Dr. Herriot Tabuteau M.D.
- Employees 712